Journal for ImmunoTherapy of Cancer: 9 (11)

Basic tumor immunology

Original research: Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion (25 November, 2021)
Anna Morena D'Alise, Guido Leoni, Maria De Lucia, Francesca Langone, Linda Nocchi, Fabio Giovanni Tucci, Elisa Micarelli, Gabriella Cotugno, Fulvia Troise, Irene Garzia, Rosa Vitale, Veronica Bignone, Elena Di Matteo, Rosa Bartolomeo, Deborah H Charych, Armin Lahm, Jonathan Zalevsky, Alfredo Nicosia, Elisa Scarselli
Original research: Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma (17 November, 2021)
Wenyong Huang, Dongmei Ye, Wenjing He, Xiaoshun He, Xiaomin Shi, Yifang Gao
Original research:
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism
(1 November, 2021)
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensson, Fanglei You, Carly Campbell, David Witty, Mike Kelly, Stephen Blakemore, Phil Jeffrey, Kevin McDonnell, Philip Brandish, Nicholas Keen
Original research: DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma (4 November, 2021)
Allison A Fitzgerald, Shangzi Wang, Veena Agarwal, Emily F Marcisak, Annie Zuo, Sandra A Jablonski, Melanie Loth, Elana J Fertig, John MacDougall, Eugene Zhukovsky, Shubhendu Trivedi, Dimple Bhatia, Vince O'Neill, Louis M Weiner

Clinical/translational cancer immunotherapy

Original research: Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis (29 November, 2021)
Yifei Ma, Nianqi Liu, Youlong Wang, Jiling Zeng, Ying-Ying Hu, Wu Hao, Huazheng Shi, Pengfei Zhu, Jun Lv, Wei Fan, Xinjia Wang
Original research: Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 (25 November, 2021)
Abbass Darwich, Alessandra Silvestri, Mohamed-Reda Benmebarek, Juliette Mouriès, Bruno Cadilha, Alessia Melacarne, Lapo Morelli, Domenico Supino, Alexandre Taleb, Hannah Obeck, Claudio Sustmann, Agnese Losurdo, Giovanna Masci, Giuseppe Curigliano, Sebastian Kobold, Giuseppe Penna, Maria Rescigno
Original research: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds (23 November, 2021)
Eline van Diest, Patricia Hernández López, Angelo D Meringa, Anna Vyborova, Froso Karaiskaki, Sabine Heijhuurs, Jan Gumathi Bormin, Sanne van Dooremalen, Mara J T Nicolasen, Lucrezia C D E Gatti, Inez Johanna, Trudy Straetemans, Zsolt Sebestyén, Dennis X Beringer, Jürgen Kuball
Original research: Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study (23 November, 2021)
Sara Lonardi, Alessandra Anna Prete, Federica Morano, Marco Messina, Vincenzo Formica, Domenico Cristiano Corsi, Corrado Orciuolo, Giovanni Luca Frassineti, Maria Giulia Zampino, Mariaelena Casagrande, Gianluca Masi, Monica Ronzoni, Mario Scartozzi, Angela Buonadonna, Stefania Mosconi, Margherita Ratti, Andrea Sartore-Bianchi, Emiliano Tamburini, Michele Prisciandaro, Francesca Bergamo, Massimiliano Spada, Salvatore Corallo, Valentina Vettore, Fotios Loupakis, Matteo Fassan, Paola Del Bianco, Vittorina Zagonel, Filippo Pietrantonio
Original research: Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 (19 November, 2021)
Meredith M Regan, Charlene M Mantia, Lillian Werner, Ahmad A Tarhini, James Larkin, F Stephen Hodi, Jedd Wolchok, Michael A Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings, Sandra Re, Wim van Dijck, David F McDermott, Michael B Atkins
Original research: Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors (19 November, 2021)
Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis
Original research: Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study (17 November, 2021)
Fangwen Zou, David Faleck, Anusha Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S Ernstoff, Isabella C Glitza Oliva, Stephen Hanauer, Jennifer McQuade, Michel Obeid, Amishi Shah, David M Richards, Elad Sharon, Jedd Wolchok, John Thompson, Yinghong Wang
Original research: Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids (17 November, 2021)
Qingda Meng, Shanshan Xie, G Kenneth Gray, Mohammad H Dezfulian, Omar Gandarilla, Weilin Li, Ling Huang, Dipikaa Akshinthala, Elizabeth Ferrer, Catherine Conahan, Sofia Perea Del Pino, Joseph Grossman, Stephen J Elledge, Manuel Hidalgo, Senthil K Muthuswamy
Original research: Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma (15 November, 2021)
Walter J Storkus, Deena Maurer, Yan Lin, Fei Ding, Anamika Bose, Devin Lowe, Amy Rose, Melissa DeMark, Lilit Karapetyan, Jennifer L Taylor, Manoj Chelvanambi, Ronald J Fecek, Jessica N Filderman, Timothy J Looney, Lauren Miller, Elizabeth Linch, Geoffrey M Lowman, Pawel Kalinski, Lisa H Butterfield, Ahmad Tarhini, Hussein Tawbi, John M Kirkwood
Original research: Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release (15 November, 2021)
Nadine Aschmoneit, Lennart Kühl, Oliver Seifert, Roland E Kontermann
Original research: Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial (15 November, 2021)
Yijun Hua, Rui You, Zhiqiang Wang, Peiyu Huang, Mei Lin, Yanfeng Ouyang, Yulong Xie, Xiong Zou, Youping Liu, Chongyang Duan, Yonglong Liu, Chenmei Gu, Rongzeng Liu, Qi Yang, Rou Jiang, Mengxia Zhang, Xi Ding, Siyuan Chen, Chao Lin, Rui Sun, Mingyuan Chen
Original research: Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial (15 November, 2021)
Oliver Klein, Damien Kee, Bo Gao, Ben Markman, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Linda Mileshkin, Jodie Palmer, Matteo Carlino, Andreas Behren, Jonathan Cebon
Original research: Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial (12 November, 2021)
Patrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, Evisa Gjini, Kristen D Felt, Jacquelyn O Wolff, Elizabeth I Buchbinder, Rizwan Haq, Ryan J Sullivan, Donald P Lawrence, David F McDermott, Mariano Severgnini, Anita Giobbie-Hurder, Scott J Rodig, F Stephen Hodi
Original research:
Selective IL-1 activity on CD8⁺ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
(12 November, 2021)
Bram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint, Elianne Burg, Stéphane Plaisance, Frank Peelman, Anje Cauwels, Gilles Uzé, Niko Kley, Sarah Gerlo, Jan Tavernier
Original research: Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study (9 November, 2021)
Kunyuan Wang, Ying Xia, Yun Zhu, Wenxuan Yu, Yabing Guo, Li Liu
Original research: Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer (1 November, 2021)
Zhenyu Lin, Ming Cai, Peng Zhang, Gang Li, Tao Liu, Xin Li, Kailin Cai, Xiu Nie, Jing Wang, Junli Liu, Hongli Liu, Weikang Zhang, Jingbo Gao, Chuanqing Wu, Linfang Wang, Jun Fan, Lan Zhang, Zheng Wang, Zhiguo Hou, Chi Ma, Kunyu Yang, Gang Wu, Kaixiong Tao, Tao Zhang
Original research: Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer (1 November, 2021)
Shaoming Zhu, A-Hong Ma, Zheng Zhu, Elio Adib, Ting Rao, Na Li, Kaiyuan Ni, Veera Chandra Sekhar Reddy Chittepu, Rao Prabhala, Juan Garisto Risco, David Kwiatkowski, Kent Mouw, Guru Sonpavde, Fan Cheng, Chong-xian Pan

Commentary

Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study (19 November, 2021)
Ryan Sun, Zachary McCaw, Lu Tian, Hajime Uno, Fangxin Hong, Dae Hyun Kim, Lee-Jen Wei
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer (8 November, 2021)
Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong
Letter to the editor from Pant et al
(1 November, 2021)
Shubham Pant, Justin T Moyers, Aung Naing

Hypothesis

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups (18 November, 2021)
David Hsiehchen, Magdalena Espinoza, Cristina Valero, Chul Ahn, Luc G T Morris

Immunotherapy biomarkers

Original research: Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer (25 November, 2021)
Joao V Alessi, Biagio Ricciuti, Stephanie L Alden, Arrien A Bertram, Jessica J Lin, Mustafa Sakhi, Mizuki Nishino, Victor R Vaz, James Lindsay, Madison M Turner, Kathleen Pfaff, Bijaya Sharma, Kristen D Felt, Scott J. Rodig, Justin F. Gainor, Mark M. Awad
Original research:
Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
(23 November, 2021)
Andrew D Kelly, Karthikeyan Murugesan, Zheng Kuang, Meagan Montesion, Jeffrey S Ross, Lee A Albacker, Richard S P Huang, Douglas I Lin, Umut Demirci, James Creeden
Original research: A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma (18 November, 2021)
Andreas Stefan Brendlin, Felix Peisen, Haidara Almansour, Saif Afat, Thomas Eigentler, Teresa Amaral, Sebastian Faby, Adria Font Calvarons, Konstantin Nikolaou, Ahmed E Othman
Original research: Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes (18 November, 2021)
Xiaofeng Chen, Deqiang Wang, Jing Liu, Jingrong Qiu, Jun Zhou, Jieer Ying, Yan Shi, Zhaoxia Wang, Haizhou Lou, Jiuwei Cui, Jingdong Zhang, Yunpeng Liu, Fengjiao Zhao, Lanlan Pan, Jianyi Zhao, Dongqin Zhu, Shiqing Chen, Xiangcheng Li, Xue Li, Liuqing Zhu, Yang Shao, Yongqian Shu
Original research: TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment (18 November, 2021)
Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Toshihide Ueno, Joji Nagasaki, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yasuhiro Nakamura, Tomonori Kawasaki, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Yuzuru Ikehara, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Hiroyuki Matsue, Yosuke Togashi
Original research: Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer (18 November, 2021)
Jenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, Daniel M Borras, Yani Berckmans, Roxanne Wouters, Raquel S Laureano, Thais Baert, Louis Boon, Chiara Landolfo, Antonia Carla Testa, Daniela Fischerova, Caroline Van Holsbeke, Tom Bourne, Valentina Chiappa, Wouter Froyman, Dominique Schols, Patrizia Agostinis, Dirk Timmerman, Sabine Tejpar, Ignace Vergote, An Coosemans, Abhishek D Garg

Immune cell therapies and immune cell engineering

Original research: Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer (23 November, 2021)
Saisha A Nalawade, Paul Shafer, Pradip Bajgain, Mary K McKenna, Arushana Ali, Lauren Kelly, Jarrett Joubert, Stephen Gottschalk, Norihiro Watanabe, Ann Leen, Robin Parihar, Juan Fernando Vera Valdes, Valentina Hoyos
Original research: Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants (22 November, 2021)
Enrique Conde, Enric Vercher, Marta Soria-Castellano, Jesús Suarez-Olmos, Uxua Mancheño, Edurne Elizalde, M Luis Rodriguez, Javier Glez-Vaz, Noelia Casares, Estefanía Rodríguez-García, Mirja Hommel, Gloria González-Aseguinolaza, Iratxe Uranga-Murillo, Julian Pardo, Gorka Alkorta, Ignacio Melero, Juan Lasarte, Sandra Hervas-Stubbs

Oncolytic and local immunotherapy

Original research: Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy (25 November, 2021)
Maite Alvarez, Carmen Molina, Carlos E De Andrea, Myriam Fernandez-Sendin, Maria Villalba, Jose Gonzalez-Gomariz, Maria Carmen Ochoa, Alvaro Teijeira, Javier Glez-Vaz, Fernando Aranda, Miguel F Sanmamed, Maria E Rodriguez-Ruiz, Xinyi Fan, Wen H Shen, Pedro Berraondo, Marisol Quintero, Ignacio Melero
Original research: Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy (23 November, 2021)
Luis Enrique Munoz, Lei Huang, Ramireddy Bommireddy, Richa Sharma, Lenore Monterroza, Rohini N. Guin, Sarah G. Samaranayake, Christopher D. Pack, Sampath Ramachandiran, Shaker J.C. Reddy, Mala Shanmugam, Periasamy Selvaraj
Original research: VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects (9 November, 2021)
Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente, Rafael Álvarez, Ana Mato-Berciano, Marta Gimenez-Alejandre, Sara Morgado, Alba Rodríguez-García, Maria V Maliandi, M Carmen Riesco, Rafael Moreno, Mireia M Ginestà, Mercedes Perez-Carreras, Joan B Gornals, Susana Prados, Sofía Perea, Gabriel Capella, Ramon Alemany, Ramon Salazar, Emma Blasi, Carmen Blasco, Manel Cascallo, Manuel Hidalgo
Original research:
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
(1 November, 2021)
Yu-Chao Zhu, Hany M Elsheikha, Jian-Hua Wang, Shuai Fang, Jun-Jun He, Xing-Quan Zhu, Jia Chen
Original research: Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity (1 November, 2021)
Shunichi Taki, Kohei Matsuoka, Yuko Nishinaga, Kazuomi Takahashi, Hirotoshi Yasui, Chiaki Koike, Misae Shimizu, Mitsuo Sato, Kazuhide Sato

Review

T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells (19 November, 2021)
Yasmin Nouri, Robert Weinkove, Rachel Perret
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma (18 November, 2021)
Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw

Correction

Correction: Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis
(26 November, 2021)
Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
(22 November, 2021)
Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival (15 November, 2021) Free
Correction: Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy? (15 November, 2021)
Correction: Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
(15 November, 2021)
Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis (15 November, 2021)
Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma (15 November, 2021)
Correction: Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
(15 November, 2021)
Correction: Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer (9 November, 2021)
Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors (1 November, 2021)

Main menu

Table of contents

November 2021 - Volume 9 - 11

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Hypothesis

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

November 2021 - Volume 9 - 11

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Hypothesis

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction